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Epstein–Barr virus and post-transplant
lymphoproliferative disease
Post-transplant lymphoproliferative disease
(PTLD) does not refer to a single disease but to
a family of closely related disorders. These
disorders are typically associated with uncon-
trolled proliferation of B cells or (in some cases)
T cells or null cells of both T- and B-cell origin.
The reported incidence of PTLD in pediatric
patients following solid-organ transplant varies
according to the organ transplanted: combined
liver–kidney transplant up to 33%; heart trans-
plant 15%; liver transplant 10%; lung transplant
6.4%; and kidney transplant 1.2% (1–3). The
type of transplant may also influence the out-
come of patients who develop PTLD. Mortality
from PTLD in pediatric kidney transplant
patients has been reported to be as high as
48%, in liver transplants 44%, in thoracic organ
transplants (heart/lung and lung) 36%, and in
heart transplants 25% (2). In addition, PTLD
following heart transplant appears to be more
aggressive and to carry an increased probability
of progressing into NHL (4). The greatest risk of
PTLD is in children who acquire primary EBV
infection following transplantation and in those
who are treated with OKT3 for steroid-resistant
allograft rejection (5, 6). The highest mortality in
all types of solid-organ transplants occurs in
children who develop PTLD within the first
6 months following transplant (2).
The evidence that EBV is associatedwith PTLD
is convincing. Children with PTLD have a higher
incidence of primary or reactivated EBV infection
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Abstract: There is convincing evidence that Epstein–Barr virus (EBV) is
associated with post-transplant lymphoproliferative disease (PTLD).
Primary EBV infection following transplantation occurs in as many as
90% of cases of PTLD in children and pretransplant EBV seronega-
tivity is a recognized risk factor for developing PTLD. Other risk fac-
tors include young age at the time of transplant, the type of transplant
that the recipient receives and the type and intensity of immunosup-
pression. The clinical presentation is often nonspecific and tissue biopsy
is necessary to establish the diagnosis. There appears to be a correlation
between PTLD and EBV viral load measured by polymerase chain re-
action (PCR) of the peripheral blood and quantitative PCR may be a
useful guide in the management of PTLD. Antiviral drugs and cyto-
megalovirus-immunoglobulin G may have a role in preventing PTLD.
Because PTLD results from functional over-immunosuppression, the
initial treatment is reduction of immunosuppression. Antiviral agents,
interferon, immuno-based monoclonal therapy, cell-based therapy and
chemotherapy also have a potential role in treating this disorder. At the
present time there is no standardized approach to the evaluation and
treatment of PTLD.
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as compared with the general transplant popula-
tion (93% vs. 30%) (7). A high level of EBVDNA
in the blood of solid-organ transplant recipients
has been shown to predict PTLD, and the EBV
genome can be detected in tumors from patients
with PTLD (8, 9). Most cases of PTLD that occur
during the first year following solid-organ trans-
plantation (early onset) are associated with recent
EBV infection. Late-developing (late-onset)
lymphomas, occurring after the first year, are less
likely to be associated with EBV infection and
usually fall into the subtype of NHL (10).
This review will focus on the risk imposed on
immunosuppressed, transplanted children for
PTLD caused by EBV infection and discuss an
approach for evaluating and treating this poten-
tially life-threatening disorder. Although the child
who has had liver transplantation will be empha-
sized, the concepts are pertinent to children who
have received other solid-organ transplants.
Epstein–Barr virus
EBV infection
EBV is a DNA virus that infects B cells. EBV
infection typically begins in the oropharyngeal
epithelium. The first step in virus–cell interaction
involves attachment of the major envelope glyco-
protein, gp350, of the virus with the CD21
molecule on the membrane of the B cell (11). As
the oropharyngeal (replicative) EBV infection
resolves, an inactive state (latency) follows, with
EBV present in small numbers of B cells (12).
EBV induces and controls B-cell proliferation in a
process referred to as immortalization, and results
in an increase in the number of infected cells prior
to virus production and cell lysis (13). After
receiving an appropriate stimulus, production of
virions resumes in a process called reactivation.
Virus-driven lymphoproliferation of B cells is
characterized by the expression of at least eight
viral genes. These include six nuclear proteins
(EBNA-1, -2, -3A, -3B, -3C and -LP) and two
latent membrane proteins (LMP-1, -2). In addi-
tion, two non-translated, small ribonucleic acids
(EBER-1 and-2) can be identified in infected cells
(13). One of the membrane proteins (LMP-1)
specifically induces the expression of several B-
lymphocyte activation antigens and has potent
growth-altering effects on a wide variety of cells,
acting as an oncogene. LMP-1 is a transforming
protein that induces a signaling response in B
cells that mimics the CD40 surface molecule,
resulting in up-regulation of cellular adhesion
molecules, cytokine production and B-cell pro-
liferation (14). LMP-1-expressing cells are also
protected from apoptosis (15). These factors play
a role in the pathogenesis of EBV-associated
diseases and PTLD.
Cellular immune responses are the critical
component in the control of EBV infection. Early
control of the proliferation of B cells results from
NK-cell activity. Two of the latent proteins,
EBNA-2 and LMP-1, have been identified as
target antigens for EBV-specific CTLs directed
against proliferating B cells, and it is these CTLs
that subsequently check uncontrolled B-cell pro-
duction (16, 17). CTLs directed against the EBV-
lytic proteins (BZLF1, BMLF1, BRLF1, BCRF1,
BMRF1, BHRF1) are capable of eliminating cells
in which viral replication has been initiated and
are important in preventing viral spread (18).
However, the virus is never completely eradicated
and remains in a small number of latently infected
B cells for the rest of the person’s life (13).
Identifying EBV infections
Antibody responses to EBV antigens
Infection with EBV initially results in the pro-
duction of EBNA followed by expression of EA.
Production of late gene products, including the
complex of viral structural proteins collectively
termed VCA, occurs next. Appearance of the
EBV antigens results in a predictable pattern of
antibody production in the immunocompetent
child. Anti-VCA IgM appears first and is soon
followed by production of anti-EA and anti-VCA
IgG. Levels of anti-EA and anti-VCA IgM
decline within a few months. Anti-VCA IgG
remains detectable for life.
In acute infection in an immunocompetent host,
anti-VCA IgG and anti-VCA IgM are usually
detected. Anti-EA may or may not be present. In
patients who have had a recent infection, anti-
VCA IgG remains positive, while anti-VCA-IgM,
anti-EA and anti-EBNA may or may not be
found. Anti-VCA IgG and anti-EBNA are found
in patients who have had a remote infection. In
immunocompetent children previously infected
with EBV, the reappearance of anti-VCA IgM,
increased anti-VCA IgG or increasing anti-EA
titers may be used as criteria to identify reinfec-
tion. The presence of anti-EBNA excludes acute
infection. EBV serology may be misleading in
immunosuppressed children. Following acute in-
fection in patients previously EBV seronegative,
EBV-specific IgM and IgG antibodies may only
appear in very low titer or not at all. In addition,
children who were EBV seropositive prior to
transplantation may develop high EBV antibody
titers as a result of immunosuppression (19). The
anti-EBNA response is compromised in immuno-
suppressed patients, and absent or significantly
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decreased anti-EBNA titers may be associated
with PTLD (20).
PCR to identify the EBV viral load
Several studies have shown a correlation between
EBV viral load in the peripheral blood, as
measured by PCR, with PTLD (21, 22). Utilizing
the technique of semi-quantitative or quantita-
tive PCR, EBV viral loads of ‡ 40 genomes/105
PBL in children who were EBV naı̈ve prior to
transplant and of ‡ 200 genome/105 PBL in
children infected prior to transplant, are consid-
ered to be consistent with an increased risk of
PTLD (23). However, these threshold values
have not been confirmed in other series and
additional studies need to be carried out. In the
absence of the use of anti-B-cell antibody, a
decrease in the EBV viral load below 200 copies/
105 PBL is suggestive of the development of
EBV-specific immunity and implies a clinical
response to treatment (24). Viral load may also
be reported as copies/107 B cells, copies/106
PBLs, copies/lg of DNA, and copies/mL of
blood. Rowe et al. have calculated conversion
values for each assay, comparing the values to
copies/105 PBLs (Table 1) (25).
Techniques for continuous real-time PCR
monitoring have recently been developed (26,
27). Using this technique, Witte et al. (28) have
identified a complex pattern of transient eleva-
tion of PCR followed by a rapid decline in EBV
copy numbers following EBV infection. They
confirmed that rising numbers correlate with the
onset of clinical EBV disease and decline follow-
ing treatment of PTLD (28). Serial real-time
measurements may be a powerful tool for adjust-
ing the immunosuppression level in response to
EBV genome load.
RT–PCR to characterize EBV gene expression
EBV infection of B lymphocytes results in a
characteristic pattern of expression of viral genes
that can be identified by RT–PCR of the periph-
eral blood. There are three patterns of gene
expression distinguishable in the immunocompe-
tent host (29). In the latent or resting state the
mRNA for LMP2a is consistently detected. The
six viral genes (EBNA1, EBNAA2, EBNA3A,
EBNA3C, EBNALP and LMP1) that are di-
rectly implicated in the process of immortaliza-
tion may be detected in the immortalized or
proliferating state. The third pattern, the virus-
producing (or lytic) state, is characterized by the
expression of > 60 early and capsid genes. In
immunosuppressed hosts, there are two distinct
patterns of gene expression which relate to the
EBV viral load of the host. Infected patients in
whom the EBV viral load is £ 100 genomes/105
PBL have a pattern indistinguishable from the
latency pattern in healthy persons. When the
viral load is > 200 genomes/105 PBL, LMP2a
and LMP1 are persistently detectable and ac-
companied by sporadic detection of EBNA1 and
EBNA2 (29). There is a heterogeneous pattern of
gene expression in patients with PTLD (30).
However, patients with EBV viral loads of > 200
genomes/105 PBL, and with persistent or inter-
mittent expression of EBNA2 in the peripheral
blood, may be at increased risk of developing
PTLD (29).
PTLD
Risk factors for developing PTLD
Several risk factors for developing PTLD have
been identified. As much as 90% of PTLD is
triggered by a primary EBV infection occurring
in the first 3–4 months after transplant, making
pretransplant seronegativity a risk factor for the
development of PTLD (5). The type of transplant
that the recipient receives has also been recog-
nized as a risk factor for developing PTLD.
Recipients of heart, liver, lung, and intestine
allografts are at greater risk of PTLD than
patients who receive a renal allograft (1). As
primary EBV infection occurs mainly in young
solid-organ transplant patients, age at the time of
transplant is a risk factor (31). The type and
intensity of immunosuppression are recognized
risk factors. When first introduced, CsA was
associated with an increased risk for developing
PTLD (32). When tacrolimus became available it
was initially associated with a 6–10-fold increase
in the incidence of PTLD (33). However, recent
data suggest a similar risk of developing PTLD
when either agent is used, i.e. 4.3% vs. 6.6%,
respectively (34). This may be a reflection of
learning to adjust the doses of these agents and
how to use them in combination with other
immunosuppressives. Only pan-lymphocytic anti-
bodies such as OKT3 significantly increase the
Table 1. Conversion of measurements of Epstein–Barr viral load
Units
Conversion
factor Low load High load
Copies/105 PBL 1 8–200 > 200
Copies/lg DNA 3 24–600 > 600
Copies/106 PBL 10 80–2000 > 2000
Copies/mL of blood
( 2 · 106 PBL)
20 160–4000 > 4000
Copies/107 PBL 1000 104)105 > 105
PBL, peripheral blood lymphocytes.




risk of PTLD (35). Infection with CMV is also a
risk factor and is independent of the intensity of
immunosuppression. Children who are CMV
seronegative at time of transplant and receive a
liver from a CMV-seropositive donor are at
greatest risk (36).
Children with LCH have an increased risk for
developing PTLD after liver transplantation (37).
It is not clear why LCH results in an increased
incidence of PTLD. LCH has been reported to be
associated with malignant neoplasms in non-
transplant patients (38). It is possible that previ-
ous chemotherapy in transplanted patients with
LCH-associated neoplasms may contribute to
the cumulative immunosuppressive effect and the
risk of PTLD. LCH cells also produce proin-
flammatory cytokines that may predispose to the
development of PTLD (37).
Clinical presentation
The clinical symptoms of PTLD are often non-
specific. Affected children may present with fever
and malaise or with an infectious mononucleosis-
like syndrome accompanied by palpable lymph-
adenopathy. Anorexia, weight loss and diarrhea
(with or without heme-positive stools) lasting for
longer than 14 days should raise the index of
suspicion. However, up to 85% of patients
<1 yr of age may be symptom-free at the time
of the first virologic evidence of EBV infection
(39). PTLD may be confused with rejection or
infection and is often associated with the pres-
ence of opportunistic infections.
PTLD can involve nearly any organ system
and may present as disseminated disease or with
focal organ involvement, including unilateral
tonsillar enlargement. The disease may affect
any solid or hollow organ, with consequent
dysfunction of that organ. The distribution of
PTLD may be abdominal (64%), thoracic (50%),
head and neck (25%), and brain (6%) (39).
Children with abdominal PTLD may present
with hepatomegaly, splenomegaly or other pal-
pable abdominal mass. The gastrointestinal tract
is a common site of involvement. In some
patients, symptoms of PTLD are limited to the
gastrointestinal tract, resulting in anemia
(100%), gastrointestinal bleeding (100%), weight
loss (89%), fevers (89%), hypoalbuminemia
(89%), anorexia (78%), chronic diarrhea
(67%), and abdominal pain (44%) (40). Involve-
ment of the allograft is not uncommon, being
reported in 80% of lung transplants, 33% of liver
transplants, and 32% of kidney transplants (14).
The disease may be rapidly progressive or it may
wax and wane for several weeks.
Diagnosis
Tissue biopsy is necessary to establish the
diagnosis of PTLD. Excised lymph nodes diag-
nostic of PTLD usually show complete archi-
tectural effacement and contain B cells in all
stages of maturation (41). The major histologic
classification for PTLD was described by
Nalesnik et al. who defined three categories:
polymorphic; monomorphic; and minimal poly-
morphism. The polymorphic pattern consists of
a diffuse population of small lymphocytes and
large cleaved and non-cleaved cells, plasmacy-
toid cells, plasma cells and immunoblasts. The
monomorphic category is much less common
and is composed of uniform lymphoid cells at
one stage of differentiation. Typically, these
cells are either small or large, non-cleaved
lymphocytes characteristic of NHL (41). NHL
characterized by the finding of small non-
cleaved cells, phenotypically B cells, is referred
to as Burkitt’s lymphoma, while tumors con-
sisting of large non-cleaved cells may be B cell,
T cell or indeterminate (42). The T-cell infiltrate
may represent an attempt at host immune
control of the B-cell proliferation (4). The
presence of EBV within PTLD lesions may be
confirmed by in situ hybridization using an
EBER probe (9).
During the first post-transplant year the clin-
ical diagnosis is based often upon documenting
the presence of EBV infection and B-cell prolif-
eration. The laboratory findings used to identify
EBV infection in immunocompetent persons
(atypical lymphocytosis, VCA-IgM, and hetero-
phile antibodies) may or may not be present in
immunosuppressed children. The absence or loss
of anti-EBNA may precede EBV/PTLD, and the
lack of seroconversion following primary EBV
infection may be a risk factor for mortality from
EBV/PTLD (2, 43).
When PTLD is suspected, PCR for EBV
should be performed on PBL. If the EBV level
is elevated, an intensive diagnostic evaluation
should proceed, including CT scan of the chest,
abdomen and pelvis. Head CT should be per-
formed if the child exhibits neurological symp-
toms. Children with tonsillar hypertrophy should
undergo tonsillectomy and the tissue submitted
for histopathologic examination (44). PTLD may
be seen in tonsillar tissue even when EBV PCR is
inconclusive (45). Lymph node biopsies should
be performed on all patients with clinically
significant peripheral lymphadenopathy. Lapa-
roscopic biopsy of intra-abdominal lymph nodes
or masses may be necessary. Gastrointestinal
endoscopy and biopsy should be performed on
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all patients with chronic diarrhea or protein-
losing enteropathy.
Prophylaxis to prevent EBV infection from progressing
to PTLD
Antiviral treatment
Antiviral agents may have a role in preventing
PTLD. Acyclovir and ganciclovir both demon-
strate in vitro activity against the linear (replica-
ting) form of EBV but not the cyclic (latent) form
(46). Ganciclovir also limits the transformation
of lymphocytes by EBV (47). Although data
from controlled randomized trials suggest little
benefit of antiviral prophylaxis in decreasing the
incidence of PTLD, several non-randomized
studies show potential benefit (48–50). For anti-
viral prophylaxis to have any significant impact
on EBV-induced PTLD, the agent should be
present at or before the time of transmission of
EBV from the donor to the recipient. Antiviral
prophylaxis during, and for 3 months after,
administration of anti-lymphocyte antibody
may decrease the incidence of PTLD (50).
Immunoglobulin
Anecdotal reports suggest that the occurrence of
PTLD is lower in transplant recipients who
receive CMV-IgG as a component of their
therapy (51). The significant immune dysregula-
tion resulting from CMV infection may play a
role in the development of PTLD. CMV replica-
tion is associated with increased production of
cytokines potentially capable of reactivating
EBV infection and capable of altering the num-
ber and function of circulating T cells (52).
Additional mechanisms of immunomodulation
by CMV, such as transactivation of EBV genes,
are theoretically possible (53, 54). However, the
overall role of immunoglobulin therapy and the
impact of giving antibody to EBV, contained in
nearly equal amounts in intravenous immuno-
globulin preparations or hyper-IgG products
such as CMV-IgG, is uncertain (Personal Com-
munication, MedImmune, Inc., Gaithersburg,
MD, USA). Although some centers use immu-
noglobulin therapy to prevent PTLD, there are
no conclusive data to support this practice.
Treatment of PTLD
Reduction of immunosuppression therapy
As PTLD results from functional over-immuno-
suppression, the initial treatment in all patients is
a reduction in immunosuppression. Regression
of PTLD following reduction of prednisone
doses and stopping all other immunosuppressives
has been reported to occur in 23–50% of patients
(55, 56). However, it is not certain whether
immunosuppression should be stopped or re-
duced in all patients, as reducing doses of
immunosuppressants may result in allograft re-
jection. In some cases, PTLD may present with
clinical or histologic evidence which are so
suggestive of malignancy, Burkett’s-type lym-
phoma or NHL that a trial of reduced immuno-
suppression may not be warranted.
Antiviral treatment
The role of antiviral therapy in treating PTLD is
unclear. As many as 90% of EBV-infected cells
in PTLD are transformed B cells that do not
undergo lytic replication (57). Neither acyclovir
nor ganciclovir are effective in vitro against
latently infected B cells (58). However, it is
theoretically possible that ganciclovir will pre-
vent the 5–10% of affected B cells undergoing
lytic replication from producing new virus which
could infect new B-cell clones (57). Although one
report describes a patient in whom the activity of
PTLD appeared to correlate with starting and
stopping treatment with acyclovir, the efficacy of
acyclovir or ganciclovir in comparative clinical
trials has not been established (59, 60).
Interferon
IFN-a is a cytokine that increases the lytic
potential of NK cells, inhibits viral replication
and increases expression of class I MHC mole-
cules. IFN-a also promotes an environment
which enhances production of cytokines that
mediate delayed-type hypersensitivity and allow
CTLs and NK cells to thrive. There have been no
randomized trials of IFN-a for treatment of
PTLD in liver transplant patients. However,
there are case reports describing successful treat-
ment (61, 62). In one published series, IFN-a was
used following reduction of immunosuppression.
There was a complete response to therapy in
50% of patients treated for longer than 3 weeks
(63). IFN-a can be given without the risk of
infection associated with traditional chemother-
apy; however, there may be an increased risk of
rejection in patients treated with IFN-a (64).
Immuno-based monoclonal therapy
Anti-B-cell antibody trials, using chimeric
mouse/human monoclonal antibody against the
CD20 B-cell antigen, have been reported in the
treatment of PTLD (65). Preliminary results,
from a multi-center phase II study testing the
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response rate and durability of treatment with
this antibody, suggest that anti-CD20 may have
an important role in the management of PTLD
(66). In a recent report, anti-CD20 was admin-
istered to six patients with progressive dissemin-
ated PTLD or bulky lesions, and treatment
resulted in a decreased EBV load and disappear-
ance of tumor masses (67). In another series, the
1-yr survival after anti-CD20 therapy was no
more than 50%, owing to treatment-related
toxicity and infection (68). The indications
for using this agent are not yet defined. A
tumor-lysis syndrome may occur following
administration of anti-CD20, and immunoglob-
ulin synthesis may be suppressed for a number of
months (69).
Cell-based therapy
As reduction in the number of EBV-specific
CTLs allows the outgrowth of EBV-trans-
formed B cells, resulting in PTLD, restoration
of CTLs may lead to regression of PTLD.
Treatment employing adoptive-cell therapy,
where donor-derived EBV-specific CTLs are
used to restore CTLs in bone marrow-trans-
plant recipients, has been used successfully
against EBV/PTLD (70, 71) Applying this
technology to the treatment of PTLD in solid-
organ transplant recipients has remained a
significant challenge. However, Khanna et al.
have developed a protocol for activating autol-
ogous EBV-specific CTL lines from immuno-
suppressed solid-organ recipients who acquired
their EBV infection after engraftment (72).
Their results demonstrated that EBV-specific T
cells may have therapeutic potential in recipients
of solid-organ transplants.
Chemotherapy
Chemotherapy is a treatment option when PTLD
has not been responsive to other therapies or if
the patient presents with a Burkitt-like or Hodg-
kin-like tumor (73). Complete remissions have
been reported using multi-drug chemotherapy
(traditionally used to treat NHL), with as many
as 70% of patients achieving a disease-free
interval for 19 months (74). Remissions have
been achieved using a low-dose chemotherapy
regimen of cyclophosphamide (600 mg/m2) for
1 day and prednisone (2 mg/kg/day) for 5 days
administered every 3 weeks for six cycles (75).
Other treatment regimens using cyclophospha-
mide, doxorubicin, vincristine and prednisone for
Burkitt-like lymphoma, or LH 89 for Hodgkin-
like PTLD, have been well tolerated and suc-
cessful (73). Chemotherapy and withdrawal of
immunosuppression may be successfully used
without graft rejection.
Other treatments
Surgical resection and radiotherapy for anatom-
ically limited disease should be considered. Spe-
cial treatment of central nervous system PTLD
may be necessary, including systemic and intra-
thecal chemotherapy or intrathecal infusion of
B-cell monoclonal antibody (76). These interven-
tions should be accompanied by a reduction in
immunosuppression.
Approach to prevention and treatment
Several approaches have been developed in an
attempt to modify primary EBV infection or
EBV reactivation following transplantation. One
approach is to monitor relative EBV viral loads
at 3–12-month intervals post-transplantation by
EBV DNA PCR in order to assess the risk for
developing PTLD, and to make modifications in
therapy to reduce this risk (8). When threshold
values for EBV DNA PCR of ‡ 40 and ‡ 200
genomes/105 PBL are exceeded for pretransplant
seronegative and pretransplant seropositive pa-
tients, respectively, it has been suggested that
immunosuppression should be reduced, and
ganciclovir and/or CMV-IgG be initiated if
PCR values do not respond (49). Although the
initial therapeutic intervention in all sympto-
matic patients should be reduction of immuno-
suppression, it is not known just how much
reduction is required, of which agents, and for
how long this reduction needs to be instituted.
Treatment is continued until the EBV PCR levels
fall below these threshold values. However, it is
controversial whether all patients who reach
these threshold EBV DNA values require thera-
peutic changes that may place them at risk for
precipitating an episode of allograft rejection.
The relative amount of immunosuppression at
the time of the EBV primary infection or
reactivation, the patient’s history of rejection
episodes, and other host variables must be taken
into account before reducing immunosuppres-
sion based solely on PCR values. Treatment with
other agents, including chemotherapy, must be
considered when the viral load does not decrease
following these interventions and certainly if
PTLD develops. This approach is outlined in
Fig. 1.
Conclusions
The natural history of PTLD is extremely vari-
able and specific prognostic indicators are not
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well established. There are no definitive data
regarding the overall survival rate for children
who develop PTLD following liver transplanta-
tion. The clinical setting in which PTLD occurs
appears to be important in determining the
outcome. The survival rate may depend upon
the time of onset of PTLD following transplan-
tation. Generally, early-onset PTLD has a better
outcome than late-onset disease (77). Death is
not always caused by PTLD, but may occur as a
result of sepsis. Groups reported with the highest
mortality rate are patients with disseminated
disease and systemic symptoms (78). The poor
prognosis of the patients with disseminated
disease may relate to delays in diagnosis and
continued or increased immunosuppression.
Patients with a better prognosis include those with
a mononucleosis-like illness, a lymphadenopathic
presentation and single-organ involvement.
Althoughmortality is high in patientswith dissem-
inated disease and those who do not initially
respond to reduction of immunosuppression,
multi-drug chemotherapy regimens have been
successful in inducing and sustaining remission
(75). At the present time there is no standardized
approach to the evaluation and treatment of
PTLD following liver or other solid-organ trans-
plant. The only manner in which a standard
approach will be developed is through prospect-
ive, multi-centered investigation.
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